| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Multiple Myeloma | 57 | 2021 | 1064 | 10.77 | Why? |
| Denosumab | 7 | 2020 | 49 | 3.54 | Why? |
| Bone Density Conservation Agents | 11 | 2020 | 209 | 3.06 | Why? |
| Osteolysis | 10 | 2020 | 57 | 2.67 | Why? |
| Bortezomib | 13 | 2019 | 125 | 2.32 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2021 | 1573 | 1.91 | Why? |
| Paraproteinemias | 4 | 2019 | 61 | 1.82 | Why? |
| Bone Diseases | 6 | 2018 | 101 | 1.71 | Why? |
| Diphosphonates | 6 | 2020 | 121 | 1.66 | Why? |
| Carrier Proteins | 4 | 2019 | 513 | 1.46 | Why? |
| Thalassemia | 3 | 2019 | 144 | 1.43 | Why? |
| RANK Ligand | 6 | 2018 | 47 | 1.28 | Why? |
| Thalidomide | 7 | 2018 | 247 | 1.17 | Why? |
| Osteoporosis | 3 | 2019 | 410 | 1.15 | Why? |
| Hypercalcemia | 3 | 2020 | 40 | 1.11 | Why? |
| Receptor Activator of Nuclear Factor-kappa B | 3 | 2020 | 13 | 1.05 | Why? |
| Waldenstrom Macroglobulinemia | 3 | 2019 | 85 | 1.01 | Why? |
| Osteoclasts | 4 | 2018 | 67 | 0.98 | Why? |
| Antineoplastic Agents | 15 | 2021 | 3550 | 0.96 | Why? |
| Neoplasm Proteins | 2 | 2018 | 501 | 0.94 | Why? |
| Osteoblasts | 3 | 2018 | 87 | 0.88 | Why? |
| Oligopeptides | 4 | 2019 | 576 | 0.86 | Why? |
| Bone Resorption | 3 | 2019 | 61 | 0.84 | Why? |
| Immunoglobulin Light-chain Amyloidosis | 7 | 2019 | 94 | 0.82 | Why? |
| Dexamethasone | 7 | 2019 | 2055 | 0.81 | Why? |
| Bone Remodeling | 5 | 2019 | 59 | 0.81 | Why? |
| Bone Neoplasms | 4 | 2019 | 287 | 0.79 | Why? |
| Angiogenic Proteins | 1 | 2019 | 14 | 0.79 | Why? |
| Activins | 1 | 2019 | 26 | 0.79 | Why? |
| Chemokine CCL3 | 2 | 2018 | 103 | 0.78 | Why? |
| Protein Phosphatase 2 | 1 | 2018 | 18 | 0.78 | Why? |
| Bone Density | 2 | 2019 | 335 | 0.76 | Why? |
| Gaucher Disease | 1 | 2019 | 63 | 0.76 | Why? |
| Semaphorins | 1 | 2018 | 12 | 0.75 | Why? |
| Heterozygote | 1 | 2019 | 249 | 0.72 | Why? |
| AMP-Activated Protein Kinases | 1 | 2018 | 93 | 0.72 | Why? |
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 9 | 0.72 | Why? |
| beta-Thalassemia | 3 | 2019 | 200 | 0.71 | Why? |
| Vitamin E | 1 | 2018 | 128 | 0.71 | Why? |
| Angiopoietin-1 | 1 | 2017 | 25 | 0.71 | Why? |
| Antibodies, Viral | 12 | 2021 | 51949 | 0.70 | Why? |
| Osteoporosis, Postmenopausal | 1 | 2018 | 75 | 0.70 | Why? |
| Biomarkers, Tumor | 4 | 2018 | 1314 | 0.70 | Why? |
| Consolidation Chemotherapy | 1 | 2017 | 41 | 0.69 | Why? |
| Spironolactone | 1 | 2018 | 114 | 0.69 | Why? |
| Antibodies, Neutralizing | 8 | 2021 | 25288 | 0.67 | Why? |
| Neoplasm Recurrence, Local | 4 | 2019 | 1063 | 0.67 | Why? |
| Cardiotoxicity | 3 | 2018 | 365 | 0.66 | Why? |
| Mineralocorticoid Receptor Antagonists | 1 | 2018 | 203 | 0.65 | Why? |
| Doxorubicin | 1 | 2019 | 313 | 0.64 | Why? |
| Hemolysis | 1 | 2019 | 283 | 0.63 | Why? |
| Angiopoietin-2 | 1 | 2017 | 125 | 0.63 | Why? |
| Leukopenia | 1 | 2018 | 280 | 0.63 | Why? |
| Plasma Cells | 4 | 2019 | 464 | 0.56 | Why? |
| Hematology | 2 | 2019 | 649 | 0.55 | Why? |
| Anemia, Sickle Cell | 2 | 2019 | 546 | 0.51 | Why? |
| Signal Transduction | 4 | 2019 | 7207 | 0.51 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.48 | Why? |
| Immunogenicity, Vaccine | 3 | 2021 | 4624 | 0.45 | Why? |
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2016 | 33 | 0.45 | Why? |
| Metformin | 1 | 2018 | 640 | 0.45 | Why? |
| Aged | 54 | 2021 | 215776 | 0.42 | Why? |
| Plasma | 1 | 2020 | 1809 | 0.42 | Why? |
| Drug Resistance, Neoplasm | 3 | 2018 | 447 | 0.41 | Why? |
| Amyloidosis | 3 | 2017 | 178 | 0.39 | Why? |
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 907 | 0.38 | Why? |
| Leukemia, Plasma Cell | 2 | 2018 | 13 | 0.38 | Why? |
| Salvage Therapy | 4 | 2019 | 417 | 0.37 | Why? |
| Aged, 80 and over | 27 | 2021 | 88759 | 0.37 | Why? |
| Thrombophilia | 2 | 2020 | 1935 | 0.36 | Why? |
| Kaplan-Meier Estimate | 6 | 2019 | 4260 | 0.36 | Why? |
| Recurrence | 7 | 2019 | 3675 | 0.35 | Why? |
| Middle Aged | 50 | 2021 | 270681 | 0.35 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.35 | Why? |
| Retreatment | 2 | 2018 | 186 | 0.35 | Why? |
| Neoplasm, Residual | 2 | 2018 | 147 | 0.34 | Why? |
| Critical Pathways | 1 | 2018 | 1587 | 0.34 | Why? |
| Humans | 101 | 2021 | 930598 | 0.34 | Why? |
| Magnetic Resonance Imaging | 4 | 2018 | 6551 | 0.33 | Why? |
| Macrophage Inflammatory Proteins | 1 | 2005 | 14 | 0.32 | Why? |
| Bone Marrow | 3 | 2019 | 492 | 0.31 | Why? |
| Male | 53 | 2021 | 367725 | 0.30 | Why? |
| Osteoprotegerin | 3 | 2018 | 32 | 0.30 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.30 | Why? |
| Boronic Acids | 3 | 2018 | 30 | 0.30 | Why? |
| Biomarkers | 16 | 2020 | 23361 | 0.30 | Why? |
| Female | 52 | 2021 | 380317 | 0.30 | Why? |
| Immunoglobulin Light Chains | 2 | 2016 | 62 | 0.29 | Why? |
| Bone and Bones | 2 | 2017 | 235 | 0.29 | Why? |
| Practice Guidelines as Topic | 9 | 2020 | 15421 | 0.29 | Why? |
| Kinetics | 3 | 2021 | 3238 | 0.28 | Why? |
| Neoplasm Staging | 4 | 2019 | 1999 | 0.27 | Why? |
| Disease-Free Survival | 6 | 2018 | 1654 | 0.27 | Why? |
| Adult | 40 | 2021 | 244371 | 0.27 | Why? |
| Neovascularization, Pathologic | 2 | 2017 | 305 | 0.26 | Why? |
| Membrane Glycoproteins | 3 | 2017 | 2273 | 0.26 | Why? |
| Hematologic Neoplasms | 1 | 2017 | 2105 | 0.26 | Why? |
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 67 | 0.25 | Why? |
| Time-to-Treatment | 1 | 2020 | 5883 | 0.25 | Why? |
| Treatment Outcome | 21 | 2020 | 51732 | 0.24 | Why? |
| Transplantation, Autologous | 3 | 2018 | 364 | 0.24 | Why? |
| Survival Analysis | 7 | 2018 | 7592 | 0.24 | Why? |
| Drug Administration Schedule | 3 | 2018 | 2324 | 0.23 | Why? |
| Stem Cell Transplantation | 2 | 2018 | 531 | 0.23 | Why? |
| Proteasome Inhibitors | 2 | 2019 | 127 | 0.23 | Why? |
| Biopsy | 4 | 2018 | 2811 | 0.22 | Why? |
| Proteasome Endopeptidase Complex | 2 | 2019 | 249 | 0.22 | Why? |
| Prognosis | 13 | 2019 | 32490 | 0.22 | Why? |
| Life Cycle Stages | 1 | 2021 | 162 | 0.21 | Why? |
| Interleukin-15 | 1 | 2021 | 169 | 0.21 | Why? |
| Antigenic Variation | 1 | 2021 | 249 | 0.21 | Why? |
| Reticulocyte Count | 1 | 2019 | 7 | 0.20 | Why? |
| Chemokine CXCL10 | 2 | 2021 | 565 | 0.20 | Why? |
| Osteocalcin | 1 | 2019 | 31 | 0.20 | Why? |
| Procollagen | 1 | 2019 | 29 | 0.20 | Why? |
| Ribonuclease, Pancreatic | 1 | 2019 | 24 | 0.20 | Why? |
| Fibroblast Growth Factor 2 | 1 | 2019 | 77 | 0.19 | Why? |
| Collagen Type I | 1 | 2018 | 56 | 0.19 | Why? |
| Neoplasms, Plasma Cell | 1 | 2018 | 83 | 0.19 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.19 | Why? |
| Antigens | 1 | 2021 | 267 | 0.19 | Why? |
| Fractures, Spontaneous | 1 | 2018 | 15 | 0.19 | Why? |
| Placebo Effect | 1 | 2018 | 108 | 0.18 | Why? |
| Plasmacytoma | 1 | 2017 | 15 | 0.18 | Why? |
| Spinal Cord Compression | 1 | 2018 | 35 | 0.18 | Why? |
| Drosophila | 1 | 2017 | 55 | 0.18 | Why? |
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2017 | 10 | 0.18 | Why? |
| Signaling Lymphocytic Activation Molecule Family | 1 | 2017 | 22 | 0.18 | Why? |
| Whole Body Imaging | 1 | 2018 | 116 | 0.18 | Why? |
| Glycoproteins | 1 | 2003 | 615 | 0.18 | Why? |
| Induction Chemotherapy | 1 | 2019 | 149 | 0.18 | Why? |
| Refusal to Treat | 1 | 2018 | 49 | 0.18 | Why? |
| Nervous System | 1 | 2020 | 303 | 0.18 | Why? |
| Protein C | 1 | 2018 | 141 | 0.17 | Why? |
| Disease Management | 5 | 2020 | 6841 | 0.17 | Why? |
| Alkaline Phosphatase | 1 | 2019 | 257 | 0.17 | Why? |
| Glomerular Filtration Rate | 3 | 2019 | 1262 | 0.17 | Why? |
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2017 | 18 | 0.17 | Why? |
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2018 | 57 | 0.17 | Why? |
| Kidney Diseases | 4 | 2018 | 1434 | 0.17 | Why? |
| Europe | 6 | 2020 | 12702 | 0.17 | Why? |
| Growth Differentiation Factor 15 | 1 | 2018 | 89 | 0.17 | Why? |
| Tumor Microenvironment | 1 | 2019 | 264 | 0.17 | Why? |
| ADP-ribosyl Cyclase 1 | 1 | 2017 | 96 | 0.17 | Why? |
| Antibody Formation | 2 | 2021 | 4038 | 0.17 | Why? |
| Lipoproteins | 1 | 2018 | 240 | 0.17 | Why? |
| Hemostatics | 1 | 2018 | 142 | 0.17 | Why? |
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 46 | 0.17 | Why? |
| Oncology Service, Hospital | 1 | 2020 | 314 | 0.17 | Why? |
| Vasodilation | 1 | 2019 | 258 | 0.16 | Why? |
| Hematopoietic Stem Cell Mobilization | 1 | 2017 | 73 | 0.16 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.16 | Why? |
| Pelvis | 1 | 2017 | 125 | 0.16 | Why? |
| Prospective Studies | 10 | 2021 | 43301 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Testicular Neoplasms | 1 | 2017 | 91 | 0.16 | Why? |
| Leishmaniasis, Visceral | 1 | 2017 | 85 | 0.16 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.16 | Why? |
| Neoplasms | 3 | 2021 | 17251 | 0.16 | Why? |
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 162 | 0.16 | Why? |
| Antibody Specificity | 1 | 2021 | 1328 | 0.16 | Why? |
| Neovascularization, Physiologic | 1 | 2017 | 160 | 0.16 | Why? |
| Immunization, Passive | 3 | 2021 | 10067 | 0.16 | Why? |
| Greece | 5 | 2020 | 2091 | 0.16 | Why? |
| Protein-Tyrosine Kinases | 1 | 2017 | 158 | 0.16 | Why? |
| Immunocompromised Host | 3 | 2021 | 5150 | 0.15 | Why? |
| Nerve Tissue Proteins | 1 | 2018 | 319 | 0.15 | Why? |
| Thrombin | 1 | 2018 | 325 | 0.15 | Why? |
| Treatment Refusal | 1 | 2018 | 211 | 0.15 | Why? |
| Th17 Cells | 1 | 2020 | 657 | 0.15 | Why? |
| Kidney | 3 | 2018 | 3648 | 0.15 | Why? |
| Healthy Volunteers | 1 | 2021 | 1444 | 0.15 | Why? |
| Practice Patterns, Physicians' | 3 | 2018 | 4927 | 0.14 | Why? |
| Matrix Metalloproteinases | 1 | 2016 | 131 | 0.14 | Why? |
| Health Services Accessibility | 2 | 2020 | 10697 | 0.14 | Why? |
| Chemotherapy, Adjuvant | 1 | 2018 | 606 | 0.14 | Why? |
| Hyperparathyroidism, Primary | 1 | 2014 | 17 | 0.14 | Why? |
| Blood Coagulation Tests | 1 | 2020 | 855 | 0.14 | Why? |
| ADAMTS13 Protein | 1 | 2018 | 363 | 0.14 | Why? |
| Angiogenesis Inhibitors | 1 | 2019 | 395 | 0.14 | Why? |
| Aging | 2 | 2021 | 3581 | 0.14 | Why? |
| Multimodal Imaging | 1 | 2019 | 534 | 0.14 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2019 | 604 | 0.14 | Why? |
| Spine | 1 | 2017 | 292 | 0.14 | Why? |
| Hodgkin Disease | 1 | 2017 | 204 | 0.14 | Why? |
| Th1 Cells | 1 | 2020 | 1228 | 0.14 | Why? |
| Kidney Glomerulus | 1 | 2016 | 144 | 0.14 | Why? |
| Pyrazines | 3 | 2020 | 1783 | 0.14 | Why? |
| Drugs, Investigational | 1 | 2017 | 198 | 0.13 | Why? |
| Cell Adhesion Molecules | 1 | 2017 | 472 | 0.13 | Why? |
| Receptors, Cell Surface | 1 | 2018 | 586 | 0.13 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 2426 | 0.13 | Why? |
| Blood Proteins | 1 | 2017 | 551 | 0.13 | Why? |
| Renal Insufficiency | 1 | 2020 | 810 | 0.13 | Why? |
| Meta-Analysis as Topic | 1 | 2020 | 1289 | 0.12 | Why? |
| Immunotherapy, Adoptive | 1 | 2017 | 524 | 0.12 | Why? |
| Double-Blind Method | 3 | 2018 | 5988 | 0.12 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2019 | 698 | 0.12 | Why? |
| Geriatric Assessment | 2 | 2019 | 1372 | 0.12 | Why? |
| Blood Cell Count | 1 | 2018 | 1101 | 0.12 | Why? |
| Testis | 1 | 2017 | 566 | 0.12 | Why? |
| Ferritins | 2 | 2020 | 2055 | 0.12 | Why? |
| Imidazoles | 1 | 2018 | 631 | 0.12 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 1014 | 0.12 | Why? |
| Gastrointestinal Tract | 1 | 2020 | 1113 | 0.12 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.12 | Why? |
| Kidney Function Tests | 3 | 2018 | 520 | 0.11 | Why? |
| Disseminated Intravascular Coagulation | 1 | 2020 | 994 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2019 | 1387 | 0.11 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.11 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.11 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.11 | Why? |
| Venous Thromboembolism | 2 | 2020 | 4273 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2017 | 602 | 0.11 | Why? |
| Follow-Up Studies | 6 | 2019 | 17020 | 0.11 | Why? |
| Diagnostic Imaging | 1 | 2019 | 1044 | 0.11 | Why? |
| Survival Rate | 7 | 2019 | 9206 | 0.11 | Why? |
| Iron | 2 | 2008 | 619 | 0.11 | Why? |
| Risk | 2 | 2020 | 5288 | 0.10 | Why? |
| Heart | 1 | 2020 | 1791 | 0.10 | Why? |
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 1458 | 0.10 | Why? |
| Positron-Emission Tomography | 1 | 2016 | 802 | 0.10 | Why? |
| Immunotherapy | 3 | 2019 | 2421 | 0.10 | Why? |
| Cell Proliferation | 1 | 2017 | 1973 | 0.10 | Why? |
| Patient-Centered Care | 1 | 2018 | 860 | 0.10 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.10 | Why? |
| Myocardium | 2 | 2020 | 2323 | 0.10 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2017 | 1153 | 0.10 | Why? |
| Frail Elderly | 1 | 2019 | 1427 | 0.09 | Why? |
| Anemia | 3 | 2019 | 789 | 0.09 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.09 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.09 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.09 | Why? |
| Young Adult | 10 | 2021 | 93724 | 0.09 | Why? |
| Telemedicine | 1 | 2020 | 25032 | 0.09 | Why? |
| Hematinics | 1 | 2008 | 48 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.09 | Why? |
| Cytokines | 3 | 2020 | 15010 | 0.09 | Why? |
| Peptide Fragments | 1 | 2019 | 2075 | 0.09 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.09 | Why? |
| Headache | 1 | 2018 | 2257 | 0.09 | Why? |
| Animals | 6 | 2019 | 78931 | 0.09 | Why? |
| Antibodies, Monoclonal | 2 | 2017 | 8041 | 0.09 | Why? |
| Endothelial Cells | 1 | 2018 | 2048 | 0.09 | Why? |
| Asymptomatic Diseases | 2 | 2018 | 3444 | 0.09 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.09 | Why? |
| International Agencies | 2 | 2019 | 202 | 0.09 | Why? |
| C-Reactive Protein | 2 | 2020 | 7972 | 0.08 | Why? |
| Maintenance Chemotherapy | 2 | 2018 | 133 | 0.08 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.08 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.08 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.08 | Why? |
| Atherosclerosis | 1 | 2014 | 768 | 0.08 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.08 | Why? |
| Chemokine CCL4 | 1 | 2005 | 71 | 0.08 | Why? |
| B-Lymphocytes | 1 | 2020 | 4418 | 0.08 | Why? |
| Hemodynamics | 1 | 2014 | 1562 | 0.08 | Why? |
| Cell Survival | 2 | 2019 | 1581 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.07 | Why? |
| Severity of Illness Index | 4 | 2019 | 48226 | 0.07 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Time Factors | 4 | 2020 | 31397 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.07 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.07 | Why? |
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 40 | 0.07 | Why? |
| Mice | 2 | 2018 | 21357 | 0.07 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.07 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.06 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.06 | Why? |
| beta 2-Microglobulin | 1 | 2003 | 102 | 0.06 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Iron Overload | 1 | 2004 | 113 | 0.06 | Why? |
| Antisickling Agents | 1 | 2002 | 28 | 0.06 | Why? |
| Medical Oncology | 1 | 2019 | 3826 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 3 | 2021 | 37182 | 0.06 | Why? |
| Solubility | 1 | 2003 | 382 | 0.06 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.06 | Why? |
| United States | 3 | 2018 | 46150 | 0.06 | Why? |
| Clinical Trials as Topic | 1 | 2021 | 7330 | 0.06 | Why? |
| Quality of Life | 2 | 2021 | 9820 | 0.06 | Why? |
| Hydroxyurea | 1 | 2002 | 87 | 0.06 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.06 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.05 | Why? |
| Quinazolines | 1 | 2002 | 126 | 0.05 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.05 | Why? |
| Lung | 2 | 2020 | 31049 | 0.05 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.05 | Why? |
| STAT6 Transcription Factor | 1 | 2019 | 28 | 0.05 | Why? |
| Laser-Doppler Flowmetry | 1 | 2019 | 32 | 0.05 | Why? |
| Retrospective Studies | 5 | 2019 | 105322 | 0.05 | Why? |
| Comorbidity | 3 | 2019 | 34796 | 0.05 | Why? |
| Cell Line, Tumor | 2 | 2019 | 3608 | 0.05 | Why? |
| Attitude of Health Personnel | 1 | 2018 | 4741 | 0.05 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.05 | Why? |
| Lung Diseases, Obstructive | 1 | 2019 | 46 | 0.05 | Why? |
| Regional Blood Flow | 1 | 2019 | 172 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Autografts | 1 | 2018 | 78 | 0.05 | Why? |
| Risk Factors | 4 | 2021 | 71621 | 0.05 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.05 | Why? |
| Cytochrome P-450 CYP2C8 | 1 | 2017 | 6 | 0.04 | Why? |
| Leishmania donovani | 1 | 2017 | 15 | 0.04 | Why? |
| Cachexia | 1 | 2019 | 75 | 0.04 | Why? |
| Thrombomodulin | 1 | 2018 | 121 | 0.04 | Why? |
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 109 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2017 | 9335 | 0.04 | Why? |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 314 | 0.04 | Why? |
| STAT3 Transcription Factor | 1 | 2019 | 268 | 0.04 | Why? |
| Antigens, CD1 | 1 | 2017 | 31 | 0.04 | Why? |
| Bone Morphogenetic Proteins | 1 | 2017 | 25 | 0.04 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.04 | Why? |
| Carcinogenesis | 1 | 2019 | 236 | 0.04 | Why? |
| Osteogenesis | 1 | 2017 | 95 | 0.04 | Why? |
| Antiprotozoal Agents | 1 | 2017 | 83 | 0.04 | Why? |
| Drug Dosage Calculations | 1 | 2018 | 243 | 0.04 | Why? |
| RNA, Messenger | 2 | 2021 | 5131 | 0.04 | Why? |
| PPAR gamma | 1 | 2017 | 102 | 0.04 | Why? |
| Transforming Growth Factor beta | 1 | 2019 | 363 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2019 | 6543 | 0.04 | Why? |
| Acute-Phase Proteins | 1 | 2017 | 177 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2018 | 426 | 0.04 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2016 | 85 | 0.04 | Why? |
| Matrix Metalloproteinase 1 | 1 | 2016 | 60 | 0.04 | Why? |
| Matrix Metalloproteinase 3 | 1 | 2016 | 65 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Genetic Markers | 1 | 2017 | 318 | 0.04 | Why? |
| Disease Progression | 3 | 2020 | 13580 | 0.04 | Why? |
| Spirometry | 1 | 2019 | 524 | 0.04 | Why? |
| Blood Pressure | 2 | 2019 | 2198 | 0.04 | Why? |
| Amyloid | 1 | 2016 | 156 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2018 | 511 | 0.04 | Why? |
| Models, Economic | 1 | 2018 | 316 | 0.04 | Why? |
| Public Health Surveillance | 2 | 2019 | 3129 | 0.04 | Why? |
| Hematopoietic Stem Cells | 1 | 2017 | 321 | 0.04 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2016 | 211 | 0.03 | Why? |
| Immunosuppressive Agents | 1 | 2013 | 6331 | 0.03 | Why? |
| Graft Survival | 1 | 2017 | 587 | 0.03 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2018 | 782 | 0.03 | Why? |
| Parathyroid Hormone | 1 | 2014 | 98 | 0.03 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 7868 | 0.03 | Why? |
| Interleukin-8 | 1 | 2019 | 964 | 0.03 | Why? |
| Proteinuria | 1 | 2017 | 474 | 0.03 | Why? |
| Immunophenotyping | 1 | 2018 | 1290 | 0.03 | Why? |
| Consensus | 2 | 2019 | 6345 | 0.03 | Why? |
| Pulse Wave Analysis | 1 | 2014 | 221 | 0.03 | Why? |
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 502 | 0.03 | Why? |
| Carotid Intima-Media Thickness | 1 | 2014 | 179 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2018 | 11497 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Virus Attachment | 1 | 2020 | 1259 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Postmenopause | 1 | 2014 | 160 | 0.03 | Why? |
| von Willebrand Factor | 1 | 2018 | 668 | 0.03 | Why? |
| Lymphoma | 1 | 2017 | 522 | 0.03 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2018 | 665 | 0.03 | Why? |
| Creatinine | 1 | 2018 | 1443 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2003 | 5440 | 0.03 | Why? |
| Radiopharmaceuticals | 1 | 2017 | 763 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2019 | 1755 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.03 | Why? |
| Leukocytes, Mononuclear | 1 | 2021 | 2115 | 0.03 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2002 | 1671 | 0.03 | Why? |
| Rituximab | 1 | 2019 | 1096 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Health Expenditures | 1 | 2018 | 904 | 0.03 | Why? |
| Liver | 1 | 2004 | 4007 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Image Processing, Computer-Assisted | 1 | 2018 | 1383 | 0.02 | Why? |
| Amides | 1 | 2020 | 1864 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2021 | 3567 | 0.02 | Why? |
| Molecular Targeted Therapy | 1 | 2018 | 1579 | 0.02 | Why? |
| Renal Replacement Therapy | 1 | 2018 | 1530 | 0.02 | Why? |
| Proteomics | 1 | 2019 | 2481 | 0.02 | Why? |
| Immunohistochemistry | 1 | 2016 | 2275 | 0.02 | Why? |
| Obesity, Morbid | 1 | 2019 | 1340 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Antioxidants | 1 | 2017 | 1593 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2019 | 4758 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.02 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.02 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.02 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.02 | Why? |
| Anemia, Iron-Deficiency | 1 | 2008 | 210 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Palliative Care | 1 | 2020 | 2665 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2015 | 3776 | 0.02 | Why? |
| International Cooperation | 1 | 2019 | 3436 | 0.02 | Why? |
| Blood Coagulation | 1 | 2018 | 2768 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Smoking | 1 | 2019 | 3358 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Immunoassay | 1 | 2021 | 4485 | 0.02 | Why? |
| Tumor Burden | 1 | 2006 | 369 | 0.02 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.02 | Why? |
| France | 1 | 2020 | 12074 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Infusions, Intravenous | 1 | 2008 | 1224 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Thrombocytosis | 1 | 2002 | 21 | 0.01 | Why? |
| Transfusion Reaction | 1 | 2004 | 245 | 0.01 | Why? |
| Interleukin-6 | 1 | 2019 | 7522 | 0.01 | Why? |
| Analysis of Variance | 1 | 2004 | 950 | 0.01 | Why? |
| Statistics, Nonparametric | 1 | 2004 | 1008 | 0.01 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.01 | Why? |
| Breast Neoplasms | 1 | 2019 | 3633 | 0.01 | Why? |
| Renal Dialysis | 1 | 2017 | 4358 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2021 | 22971 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Vitamin D | 1 | 2014 | 2904 | 0.01 | Why? |
| Remission Induction | 1 | 2002 | 950 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2017 | 53120 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Cohort Studies | 1 | 2020 | 36005 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Platelet Count | 1 | 2002 | 1381 | 0.01 | Why? |
| Thrombosis | 1 | 2017 | 7504 | 0.01 | Why? |
| Critical Illness | 1 | 2018 | 17281 | 0.01 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.01 | Why? |
| Italy | 1 | 2018 | 38444 | 0.01 | Why? |
| Leukocyte Count | 1 | 2002 | 3178 | 0.01 | Why? |